on GENOWAY (EPA:ALGEN)
GenOway: Solid 2025 annual results despite a slight decrease in revenue
GenOway closed 2025 with an EBITDA margin of 21%, despite a €1.1 million decrease in revenue, which settled at €21.0 million. The ROUTE50+ strategic plan enabled the company to maintain profitability above expectations, with an EBITDA margin exceeding the target of 15%. Commercial investments and research and development weighed on performance, but total savings of €2.2 million are expected by 2026.
The company anticipates double-digit organic growth in 2026, driven by international expansion, particularly in Asia, and the launch of new Catalogue model ranges. Shareholders' equity has increased to €25 million, supported by a capital increase.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENOWAY news